Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

ded December 31, 2007, the Company reported a net loss of $23.3 million, or $0.79 per share, compared with a net loss of $56.8 million, or $2.52 per share, for the year ended December 31, 2006. (All share and per-share data have been retroactively adjusted to account for the effect of a 1-for-6 reverse stock split on July 13, 2007.)

Net product sales of $0.3 million for the fourth quarter of 2007 increased from $0.1 million for the fourth quarter of 2006, primarily due to a reduction in a provision for sales returns of Ganite(R) of $0.1 million. Net product sales for the year ended December 31, 2007 of $0.6 million declined from the prior-year period of $0.7 million as product sales in 2007 and 2006 included favorable adjustments to a reserve for returns of Ganite of $0.1 million and $0.3 million, respectively. Operating expenses for the fourth quarter and the year ended December 31, 2007 declined from their comparable prior-year periods, as the prior year included a buildup of sales, marketing and manufacturing expenses incurred in preparation for a possible commercial launch of Genasense. In addition, lower expenses in 2007 reflect the impact of a staff reduction in December 2006.

In the fourth quarter of 2006, the Company recorded an expense of $5.3 million that provided for the issuance of 2 million shares of Genta common stock, for a settlement in principle of class action litigation. The expense is net of insurance recovery of $18.0 million. At December 31, 2007, the revised estimated value of the common shares portion of the litigation settlement is $1.0 million based on a closing price of Genta's common stock of $0.52 per share, resulting in a reduction in the provision of $1.6 million and $4.2 million for the fourth quarter and year ended December 31, 2007, respectively.

Also in the fourth quarter of 2006, we accounted for the impairment of prepaid royalties and recorded a write-off of this asset of $1.3 million due to the non-approvabl
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "Medical Device Studies: Clinical Evidence ... to their offering. This course ... involved in gathering clinical evidence required for medical ... required for all medical devices and the emphasis ...
(Date:9/2/2015)... Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... Chief Financial Officer of Neurocrine Biosciences, will be presenting ... New York City . The live ... ET (8:25am PT).  The presentation will be webcast and ... http://www.neurocrine.com .   Listeners are encouraged to ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. Advances in understanding of ... new avenues and possibilities for improved drug delivery ... enzymes, and receptors that control the penetration of ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... N.H., Dec. 14, 2011 Novocure, a commercial ... of three former senior OSI Pharmaceuticals executives to ... is responsible for bringing the company,s new tumor ...   Peter M. Melnyk has joined ...
... 2011  The editors of IndustryWeek have selected 10 honorees for ... Fame. IndustryWeek is the premiere publication serving executive and ... history of acknowledging the leaders of manufacturing operations through distinguishing ... Best Plants. Through the IW Manufacturing ...
Cached Medicine Technology:Novocure Adds Three Senior Oncology Executives to its Global Management Team 2Novocure Adds Three Senior Oncology Executives to its Global Management Team 3Novocure Adds Three Senior Oncology Executives to its Global Management Team 4National Magazine Inducts 10 Manufacturing Leaders Into the IW Manufacturing Hall of Fame 2National Magazine Inducts 10 Manufacturing Leaders Into the IW Manufacturing Hall of Fame 3National Magazine Inducts 10 Manufacturing Leaders Into the IW Manufacturing Hall of Fame 4
(Date:9/2/2015)... ... 2015 , ... One can hardly argue against the fact that more and ... personal computers. These devices are being used as GPS, to make purchases, and yes, ... apps, STD positive singles can now join the prestigious social ranks of e-dating. ...
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system ... a complex of the Cas9 nuclease with either a chimeric single guide RNA (sgRNA) ... ability of any given guide RNA (sgRNA or crRNA) to create a break in ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading ... two leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation ... Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver the morning ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Telehealth represents ... Well Corp., contracted to handle the telehealth services of more than 12 Blues plan ... and Blue Shield Plans takes a look this growing trend, interviewing executives at Capital ...
(Date:9/2/2015)... ... , ... Date and time: Oct. 3, 2015, 9 a.m. to 4 p.m. ... Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , The Quakertown, ... author Sam Keen based on his new book which he co-authored with his son, ...
Breaking Medicine News(10 mins):Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2
... blood cells immune system ,soldiers, get to the site ... along the lining of the blood vessel gripping it tightly ... the while searching for temporary ,road signs, made of special adhesion ... barrier so they can get to the damaged tissue. ...
... its Industry Quarterly publications focused on recent events ... and healthcare IT industriesWALTHAM, Mass., May 4 ... medical technology market intelligence, has recently released the ... (IQ) publications highlighting the most recent trends ...
... This Mother,s Day, kids of all ages can treat ... visit http://www.hydromassage.com/mothersday to download ... certificate (for the young at heart) that entitles their mom ... are over 700 locations in 49 states participating in the ...
... MMR Information Systems, Inc. (OTC Bulletin Board: MMRF), ... (collectively, "MMR") provides consumer-controlled Personal Health Records ("PHRs") ... deposit box storage solutions ( www.myesafedepositbox.com ... previously filed current report on Form 8-K dated ...
... U.S. experts say , , MONDAY, May 4 (HealthDay News) -- ... to one usually seen in pigs emerges, spreads and sets ... familiar? Just such a swine flu outbreak occurred decades ago, ... such an outbreak doesn,t necessarily lead to mass mortality or ...
... Board of Directors as it Focuses on Continued GrowthSYLMAR, ... nation,s leading specialty distributor of health care products in ... today that it has acquired Blue Ridge Medical, Inc., ... The company plans to merge Blue Ridge with ...
Cached Medicine News:Health News:Weizmann Institute scientists show white blood cells move like millipedes 2Health News:Despite the Economic Downturn, Long-Term Growth Potential in the US Dental Biomaterial Market Remains Robust 2Health News:HydroMassage Lets Kids Treat Mom to Free Massage this Mother's Day 2Health News:MyMedicalRecords, Inc. Stand-Alone Audited Financial Statements for the Period Ending December 31, 2008 to be Filed with the SEC Today, Monday, May 4, 2009 2Health News:MyMedicalRecords, Inc. Stand-Alone Audited Financial Statements for the Period Ending December 31, 2008 to be Filed with the SEC Today, Monday, May 4, 2009 3Health News:MyMedicalRecords, Inc. Stand-Alone Audited Financial Statements for the Period Ending December 31, 2008 to be Filed with the SEC Today, Monday, May 4, 2009 4Health News:MyMedicalRecords, Inc. Stand-Alone Audited Financial Statements for the Period Ending December 31, 2008 to be Filed with the SEC Today, Monday, May 4, 2009 5Health News:MyMedicalRecords, Inc. Stand-Alone Audited Financial Statements for the Period Ending December 31, 2008 to be Filed with the SEC Today, Monday, May 4, 2009 6Health News:1976 Swine Flu Outbreak Offers Echoes, Lessons Today 2Health News:1976 Swine Flu Outbreak Offers Echoes, Lessons Today 3Health News:1976 Swine Flu Outbreak Offers Echoes, Lessons Today 4Health News:Sarnova Announces Acquisition to Expand Bound Tree Medical Business 2Health News:Sarnova Announces Acquisition to Expand Bound Tree Medical Business 3
... opening to block tear drainage through the canaliculus, ... dry eye symptoms:, Indicated for use in ... dry eye components of various ocular surface diseases, ... dry eye related complications and to enhance the ...
The collagen intracanicular plugs have a smooth proprietary finish that simplifies insertion of the plug. Collagen plugs are ideal for short term, diagnostic and post-surgical occlusion. Plugs are 2m...
Form should always follow function. Thats why EagleVision created the FlexPlug, the only tapered shaft punctum plug with contouring traction ribs. Designed to provide the ultimate in flexibility, fix...
... Steerability - Use the Attain Prevail's ... catheters and guide wires, to obtain the ... Inject contrast media for improved visualization of ... needed with tip deflection. Telescoping - ...
Medicine Products: